This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Randomized Controlled Trial

. 2008 Jan;9(1):4-5.

doi: 10.1016/S1470-2045(07)70389-3.

ERBB2 status and outcome of endocrine treatment

PMID: 18177812
DOI: 10.1016/S1470-2045(07)70389-3

Randomized Controlled Trial

ERBB2 status and outcome of endocrine treatment

W R Miller. Lancet Oncol. 2008 Jan.

. 2008 Jan;9(1):4-5.

doi: 10.1016/S1470-2045(07)70389-3.

Author

PMID: 18177812
DOI: 10.1016/S1470-2045(07)70389-3

No abstract available

PubMed Disclaimer

Comment on

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Rasmussen BB, et al. Lancet Oncol. 2008 Jan;9(1):23-8. doi: 10.1016/S1470-2045(07)70386-8. Epub 2007 Dec 20. Lancet Oncol. 2008. PMID: 18083065 Clinical Trial.

Similar articles

Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Sawada S, Sato K, Kusuhara M, Ayaori M, Yonemura A, Tamaki K, Hiraide H, Mochizuki H, Ohsuzu F. Sawada S, et al. Acta Oncol. 2005;44(2):134-41. doi: 10.1080/02841860510007585. Acta Oncol. 2005. PMID: 15788292 Clinical Trial.
Long-term outcomes of aromatase inhibition for breast cancer.
Toi M. Toi M. Lancet Oncol. 2008 Jan;9(1):8-10. doi: 10.1016/S1470-2045(07)70392-3. Lancet Oncol. 2008. PMID: 18177815 No abstract available.
Extended adjuvant therapy for breast cancer--how much is enough?
Prowell TM, Stearns V. Prowell TM, et al. J Natl Cancer Inst. 2007 Dec 19;99(24):1825-7. doi: 10.1093/jnci/djm264. Epub 2007 Dec 11. J Natl Cancer Inst. 2007. PMID: 18073372 No abstract available.
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G. Grana G. J Surg Oncol. 2006 Jun 1;93(7):585-92. doi: 10.1002/jso.20564. J Surg Oncol. 2006. PMID: 16705732 Review.
Targeting breast cancer with hormonal treatment options.
Mellington TE, Fields MM. Mellington TE, et al. Nurse Pract. 2008 May;33(5):17-22; quiz 22-3. doi: 10.1097/01.NPR.0000317483.12297.0a. Nurse Pract. 2008. PMID: 18458623 Review. No abstract available.

See all similar articles

Cited by

Understanding the mechanisms of aromatase inhibitor resistance.
Miller WR, Larionov AA. Miller WR, et al. Breast Cancer Res. 2012 Jan 19;14(1):201. doi: 10.1186/bcr2931. Breast Cancer Res. 2012. PMID: 22277572 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal